

REMARKS

Applicants respectfully request reconsideration.

Claims 1-28 were pending in this application. Claims 4, 7, 8, 13, 16, 17 and 19-28 have been withdrawn as being drawn to nonelected inventions. Applicants reserve the right to pursue the subject matter of the originally filed claims in one or more continuing applications. Claims 1-3, 5, 6, 9-12, 14, 15, and 18 are currently under examination. No amendments of the claims have been made and no new matter has been added.

Double Patenting Rejection

The Examiner has rejected claims 1-3, 5, 6, 9-12, 14, 15 and 18 on the ground of nonstatutory obviousness-type double patenting as allegedly being unpatentable over claims 1-6 of U.S. Patent No. 6,156,311 to Strickland et al. The Examiner has further rejected claims 1-3, 5, 6, 9-12, 14, 15 and 18 on the ground of nonstatutory obviousness-type double patenting as allegedly being unpatentable over claims 1-7 of U.S. Patent No. 6,447,775 to Strickland et al. The Examiner argues that lipoprotein receptor-related protein (LRP) and very low density lipoprotein receptor (VLDL-R) are “obvious variants” of one another because LRP and VLDL-R are in “the same receptor family.”

Applicants respectfully disagree. Applicants submit that lipoprotein receptor-related protein and very low density lipoprotein receptor are not “obvious variants” of one another as alleged by the Examiner. The prior art teaches that the LDL receptor (LDL-R) family consists of at least four members, LRP, VLDL-R, LDL-R, and glycoprotein 330 (gp330) (see U.S. Patent No. 6,156,311 to Strickland et al. column 2, line 21-26) that have dissimilar properties and functions. For example, Willnow et al. (J Biol Chem 267:26172-26180 (1992)), cited in Strickland et al., teach that LRP “is much larger than LDL receptor (4525 versus 839 amino acids)” and that “LRP does not bind LDL, but it does bind β -migrating very low density lipoproteins (β -VLDL)” (see, page 26172, right column, 3rd paragraph), demonstrating that LRP

and LDL-R diverge not only structurally but also functionally. This example of divergent structural and functional characteristics of LRP and LDL-R demonstrates that members in the LDL receptor family (i.e., the “same receptor family”) are not “obvious variants” of one another, as alleged by the Examiner. In further support of this notion, Applicants note that LRP is also structurally very dissimilar to VLDL-R. To demonstrate this point, Applicants have performed a sequence alignment of a human LRP amino acid sequence (GeneBank GI No.: 3493576) and a human VLDL-R amino acid sequence (GeneBank GI No.: 688371) (*see Exhibit A for sequence alignment*). Applicants note that these two amino acid sequences share an overall identity of only 7.2%, LRP being much larger than VLDL-R.

Furthermore, Applicants submit that it is well known in the art that the amino acid sequence of a polypeptide determines its structural and functional properties, including binding to other proteins or other molecules. For example, Kaye et al. (Proc. Natl. Acad. Sci. USA, 1990 Vol. 87; pp. 6922-6926) (*see Exhibit B*), teach that a single amino acid substitution results in a protein defective, *inter alia*, in binding to a specific protein. In particular, Kaye et al. state that “[w]e have now demonstrated . . . that a single point mutation . . . is sufficient to generate an RB1 defective in phosphorylation and oncoprotein *binding*” (emphasis added, see page 6922, column 2: paragraph 3). It is thus evident from Kaye et al. that amino sequence is essential for protein function, including protein binding.

Based on the teachings of the prior art and the evidence presented here, showing a significant structural and functional divergence between different members of the LDL receptor family, one of ordinary skill in the art would not consider LRP and VLDL-R “obvious variants” of one another.

Therefore, the rejected claims are not obvious over claims 1-6 of U.S. Patent No. 6,156,311 to Strickland et al. or claims 1-7 of U.S. Patent No. 6,447,775 to Strickland et al. Accordingly, reconsideration and withdrawal of the rejections is respectfully requested.

Rejections under 35 U.S.C. §103

The Examiner has rejected claims 1–3, 5, 6, 9–12, 14, 15 and 18 under 35 U.S.C. §103(a) as allegedly being unpatentable over U.S. Patent No. 6,156,311 to Strickland et al. The Examiner argues that based on the teachings of Strickland et al. claims relating to reducing the amount or rate of binding of APP with VLDL-R “amount to substitution of one known equivalent for another, i.e. VLDL-R for LRP.”

Applicants respectfully disagree. A finding of obviousness is based on the factual analysis set forth in Graham v. John Deere, 383 U.S. 1, 148 USPQ 459 (1966), which was affirmed by the US Supreme Court in KSR International Co. v. Teleflex Inc., 82 USPQ2d 1385 (2007). See also MPEP 2141. The factual inquiry of Graham v. John Deere includes: 1) determining the scope and content of the prior art; 2) ascertaining the difference between the claimed invention and the prior art, considering both the prior art and the invention as a whole; and 3) resolving the level of ordinary skill in the art. Notwithstanding these factual inquiries, objective evidence of obviousness or non-obviousness must also be considered before reaching a conclusion on obviousness. Objective evidence includes: (1) the commercial success of the invention; (2) whether the invention satisfied a long felt need in the industry; (3) failure of others to find a solution to the problem at hand; and (4) unexpected results.

Applicants submit that lipoprotein receptor-related protein (LRP) and very low density lipoprotein receptor (VLDL-R) are not “known equivalents” of one another as alleged by the Examiner. As mentioned above in response to the double patenting rejection, the prior art teaches that the LDL receptor (LDL-R) family consists of at least four members, LRP, VLDL-R, LDL-R, and glycoprotein 330 (gp330) that have dissimilar properties and functions. For example, Willnow et al., cited in Strickland et al., present data that suggest that LRP and LDL-R diverge structurally and functionally. As demonstrated by Applicants above, LRP is also structurally very dissimilar from VLDL-R. These two sequences share an overall sequence identity of only 7.2%.

Based on the teachings of the prior art and the evidence presented here, showing a significant structural and functional divergence between the different members of the LDL

receptor family, one of ordinary skill in the art would not consider LRP and VLDL-R “known equivalents” of one another.

The Examiner argues that “upon reading the disclosure of the Strickland et al. patent, the skilled artisan would have recognized the desirability of developing additional methods of reducing the catabolism of APP and of treating Alzheimer’s disease.”

Applicants respectfully disagree. Upon reading the Strickland et al. patent a person of ordinary skill in the art would not have been motivated to search for additional LDL receptor family members that may interact with APP. There is no teaching or suggestion in this reference that additional LDL receptor family members, apart from LRP, would be able to interact with APP, or that it would be desirable or necessary to look for interactions of APP with additional LDL-R family members and to “improve Strickland et al.’s methods,” as suggested by the Examiner.

Guided by the very low overall sequence homology of LRP and VLDL-R and without *a priori* knowledge of the VLDL-R/APP interaction, a person of ordinary skill in the art would not have had any reason to determine if VLDL-R binds to APP, and would not have had a reasonable expectation of success of finding that VLDL-R would be likely to bind to APP. In view of the prior art, as a whole, it was a surprising result, obtained by Applicants, that VLDL-R also binds to APP and mediates APP endocytosis similar to LRP. Hence, it was unexpected that VLDL-R represents a viable target for reducing catabolism of extracellular secreted APP by disrupting the interaction of APP and VLDL-R, as instantly claimed.

The Examiner has failed to make a *prima facie* case of obviousness. Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.

CONCLUSION

In view of the above remarks, Applicants maintain that the pending application is now in condition for allowance. Allowance is respectfully requested.

Applicants believe no fee is due with this response. If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicants hereby request any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, the Director is hereby authorized to charge any deficiency or credit any overpayment in the fees filed, asserted to be filed, or which should have been filed herewith to our Deposit Account No. 23/2825, under Docket No. M0765.70061US00 from which the undersigned is authorized to draw.

Dated: December 15, 2008

Respectfully submitted,

By: /John R. Van Amsterdam/
John R. Van Amsterdam
Registration No.: 40,212
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
617.646.8000

A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding

(recessive oncogene/small-cell carcinoma/DNA tumor virus/gene transfection)

FREDERIC J. KAYE*^{†‡}, ROBERT A. KRATZKE*, JEAN L. GERSTER*[†], AND JONATHAN M. HOROWITZ[§]

*National Cancer Institute-Navy Medical Oncology Branch, National Cancer Institute, and [†]Uniformed Services University of the Health Sciences, Bethesda, MD 20814; and [§]Section of Cell Growth, Regulation and Oncogenesis, and Department of Microbiology and Immunology, Duke University Medical Center, Durham, NC 27710

Communicated by Alfred Knudson, Jr., July 2, 1990 (received for review March 20, 1990)

ABSTRACT We have previously identified a small-cell lung cancer cell line (NCI-H209) that expresses an aberrant, underphosphorylated form of the retinoblastoma protein RB1. Molecular analysis of RB1 mRNA from this cell line revealed a single point mutation within exon 21 that resulted in a nonconservative amino acid substitution (cysteine to phenylalanine) at codon 706. Stable expression of this mutant RB1 cDNA in a human cell line lacking endogenous RB1 demonstrated that this amino acid change was sufficient to inhibit phosphorylation. In addition, this cysteine-to-phenylalanine substitution also resulted in loss of RB1 binding to the simian virus 40 large tumor and adenovirus E1A transforming proteins. These results confirm the importance of exon 21 coding sequences and suggest that the cysteine residue at codon 706 may play a role in achieving a specific protein conformation essential for protein–protein interactions.

The retinoblastoma susceptibility gene (*RB1*) encodes a nuclear phosphoprotein that is expressed in all normal human and mouse cells examined to date (1–4). Mutational inactivation of *RB1* has been tightly linked with susceptibility to developing the pediatric tumor retinoblastoma and has also been associated with a limited group of nonfamilial tumors, including small-cell lung cancer (SCLC) and several types of sarcomas and carcinomas (5–13). Given that loss of RB1 function is associated with neoplastic proliferation, *RB1* has been variously termed an antioncogene, recessive oncogene, or tumor-suppressor gene. To support this hypothesis, introduction of *RB1* into *RB1*[−] cells has been reported to suppress some of the parameters of malignant transformation (13, 14).

Another distinct mechanism of *RB1* inactivation has been inferred from studies of neoplastic transformation mediated by a group of DNA tumor viruses including the adenovirus, papovavirus, and papillomaviruses. The transforming proteins of these tumor viruses (E1A, large tumor, and E7 protein, respectively) form specific complexes with a set of host cellular proteins that has recently been shown to include RB1 (15–19). The formation of these viral oncoprotein–RB1 complexes has been proposed to result in loss or attenuation of RB1 activity, thus rendering virus-infected cells devoid of the growth regulatory activity imposed by a fully functional RB1.

In view of the observation that the *RB1* product is constitutively expressed and that both mRNA and protein are long-lived, phosphorylation of RB1 has been suggested as a mechanism to regulate its activity. In support of this model, changes in the phosphorylation state of RB1 have been closely correlated with specific stages of the cell cycle (20–23). Cells arrested in the G₁ phase of the cell cycle or synchronized postmitotic cells were noted to contain pre-

dominantly un- or underphosphorylated RB1 (designated RB1^{dephos}), whereas gradual phosphorylation of RB1 (RB1^{phos}) occurred in synchronized cells just before entry of S phase. Recently, RB1^{phos} molecules have been shown to be dephosphorylated during passage through mitosis, thus replenishing the intranuclear store of RB1^{dephos} before the next G₁ phase (24). Because RB1 is dephosphorylated in resting cells and becomes phosphorylated before S phase, it has been argued that the active (growth repressor) fraction of RB1 is constituted by the subset of dephosphorylated RB1 molecules. This hypothesis is supported by experiments demonstrating that simian virus 40 large tumor antigen specifically complexes with the dephosphorylated members of the RB1 family for binding (25). To date, however, no other changes in RB1 functional activity have been directly correlated with the state of RB1 phosphorylation.

A common approach to the investigation of protein structure–function has been to study the phenotype of *in vivo* mutant products. For familial or sporadic retinoblastoma tumors, the inactivation of the gene (whether by large or subtle structural mutations) results in the complete absence of detectable RB1 (1, 2). In contrast, stable mutant RB1s have been found in a human bladder carcinoma cell line (10), a prostate carcinoma line (13), and several SCLC samples (2, 26). Molecular analysis of mRNA encoding the truncated RB1s in these samples revealed that single exons (either exons 21, 22, or 16) had been deleted from mature RB1 mRNA. With the exception of the prostate carcinoma line DU145, point mutations with the potential for altering splicing signals were identified in the *RB1* genes encoding these aberrant proteins and were presumed to deregulate exon splicing. Characterization of these truncated proteins showed they were defective both in their ability to be phosphorylated as well as to bind to simian virus 40 large tumor and adenovirus E1A transforming proteins. These, and other studies, have begun to delineate regions along the RB1, such as sequences corresponding to exon 16 and especially exons 21 and 22, which appear to be required for its normal activity.

We have now demonstrated in a well characterized SCLC cell line that a single point mutation near the beginning of exon 21, resulting in a cysteine-to-phenylalanine substitution at codon 706, is sufficient to generate an RB1 defective in phosphorylation and oncoprotein binding. This analysis directs attention to a discrete region of the encoded protein and suggests that Cys-706, or immediately adjacent residues, play an important role in normal activity of the RB1.

Abbreviations: RB1, protein encoded by the retinoblastoma susceptibility gene; SCLC, small-cell lung cancer; PCR, polymerase chain reaction.

[‡]To whom reprint requests should be addressed at: National Cancer Institute–Navy Medical Oncology Branch, Building 8, Room 5101, Naval Hospital, Bethesda, MD 20814.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

MATERIALS AND METHODS

Cell Lines. Derivation and propagation of the lung cancer cell lines were as described (27).

Western (Immunologic) Blotting. Cellular protein was extracted by lysing $\approx 5 \times 10^6$ cells in 1 ml of 50 mM Tris-HCl, pH 7.5/250 mM NaCl/5 mM EDTA/0.1% Nonidet P-40/50 mM NaF/1 mM phenylmethylsulfonyl fluoride (PMSF) containing leupeptin at 10 μ g/ml and aprotinin at 50 μ g/ml, followed by quick-freezing of the supernatant. Seventy-five micrograms of cellular protein was electrophoreted to nitrocellulose paper after separation on 7.5% SDS/PAGE and then allowed to incubate overnight at 4°C with a 1:100 dilution of monoclonal anti-RB1 antibody at 336 μ g/ml (PharMingen, San Diego). The immunoblot was subsequently incubated for 4 hr with a 1:100 dilution of polyclonal rabbit anti-mouse antibody (PharMingen) at 1.89 mg/ml, followed by a 2-hr incubation with 2.5×10^6 cpm of 125 I-labeled protein A and autoradiography.

Immunoprecipitation. Equivalent numbers of lung carcinoma cells were radiolabeled with either [35 S]methionine or [32 P]orthophosphate, and lysates were prepared as described (2). Immunoprecipitations were performed with antiserum 147 (15). Immunoprecipitates were then collected on protein A-agarose beads (BRL-Life Technologies, Gaithersburg, MD) and subjected to SDS/PAGE, fluorography, and autoradiography.

RNAse Protection Analysis. The plasmid construct, pJD18, containing a 1.5-kilobase (kb) *RB1* insert from nucleotide coordinates 1039–2537 in the vector pBluescript KS (Stratagene) was a gift from J. Dunn and B. Gallie (University of Toronto, Ontario, Canada). The *RB1* nucleotide coordinates presented here are as published (1). The vector was linearized with the restriction enzyme *Nco* I (*RB1* coordinate 1681) to generate a uniformly [32 P]UTP-labeled antisense RNA probe. Overnight hybridization at 55°C was performed by using 1×10^5 cpm of the RNA probe, and 15 μ g of total RNA was extracted from tumor cell lines. The hybridization mix was digested with RNase A, extracted with organic solvents, and precipitated with ethanol. The samples were then separated on a 6% urea/acrylamide gel and autoradiographed.

DNA Sequencing of Polymerase Chain Reaction (PCR)-Amplified cDNA. First-strand cDNA was synthesized from 3 μ g of total cellular RNA by using a 3' oligonucleotide primer from *RB1* coordinates 2395–2371 and avian myeloblastosis virus reverse transcriptase under conditions specified by the manufacturer (BRL-Life Technologies). This was followed by the addition of a 5' oligonucleotide from coordinates 1910–1935 and PCR amplification using *Thermus aquaticus* (*Taq*) DNA polymerase as specified by the manufacturer (Perkin-Elmer/Cetus). Amplified inserts were cloned into pGem4 vectors (Promega), and nucleotide sequence was determined by the dideoxy nucleotide chain-termination method (28). Nucleotide sequence was obtained from three independent PCR-amplification reactions.

Construction of Mutant *RB1*-Containing Plasmid Vectors. PCR-amplified cDNA was obtained from 3 μ g of total RNA from cell line H209 by using primers spanning *RB1* coordinate 1910 at the 5' end and *RB1* coordinate 2960 at the 3' end. The amplified fragment containing the point mutation was then digested with the unique, internal restriction enzymes *Mlu* I and *Bsm* I (New England Biolabs), and the resulting fragment was purified on an acrylamide gel and ligated into a wild-type *RB1*-containing vector from which the *Mlu* I–*Bsm* I insert had been previously removed. The entire PCR-generated region was subjected to nucleotide sequence analysis to confirm the presence of the specific point mutation and to assure that the encoded open reading frame had not been altered by *Taq* polymerase incorporation errors.

Stable Expression in *RB1*[−] Cancer Cell Line. Eukaryotic expression vectors containing either the wild-type or mutant *RB1* open reading frame were transfected via lipofection as described by the manufacturer (BRL-Life Technologies) into the *RB1*[−] SCLC cell line H187 (unpublished work). G418-resistant single clones were expanded, and whole-cell protein extracts were harvested and subjected to immunoblotting with an anti-*RB1* monoclonal antibody as outlined above.

DNA Tumor Virus Oncoprotein Binding. pGem4 vectors containing either the wild-type or mutant *RB1* open reading frame were subjected to *in vitro* transcription and translation in the presence of [35 S]methionine, as described by the manufacturer (Promega). Immunoprecipitations were performed as described (2) by using either polyclonal anti-*RB1* antiserum 147 (15) or monoclonal antibodies against adenovirus E1A M73 (29) or simian virus 40 large tumor antigen pAb416 (30).

RESULTS

In our original report of *RB1* inactivation in SCLC, we observed detectable levels of apparently normal-sized *RB1* mRNA in $\approx 40\%$ of the SCLC cell lines examined (7). Most of the SCLC lines producing *RB1* transcripts, however, either lacked or expressed aberrant forms of *RB1* (2). These observations have been confirmed (8) and strongly implicate inactivation of *RB1* as an event common to most SCLC tumors.

In the course of our analysis of SCLC tumors, an example of an aberrant *RB1* was noted in one tumor culture, NCI-H209 (2). Cell line NCI-H209 has been characterized as a "classic" SCLC line, exhibiting features of neuroendocrine differentiation (27) and also expressing elevated levels of L-MYC mRNA without *MYC* gene amplification (31). We prepared an immunoblot containing denatured cell lysates from H209 and control cells, and incubated the immobilized proteins with a monoclonal anti-*RB1* antiserum (Fig. 1A). In contrast to the normal dephosphorylated, *RB1*^{dephos}, and phosphorylated, *RB1*^{phos}, migration pattern of ≈ 110 –115 kDa seen in protein extracts from normal cells and most tumor samples, H209 cells demonstrated only a single band comigrating with the unphosphorylated, 110-kDa *RB1* species. Immunoprecipitation of [35 S]methionine-labeled H209 cell lysates with a polyclonal anti-*RB1* synthetic peptide serum also resulted in a single discrete species of *RB1* that comi-




FIG. 1. (A) Immunoblot analysis. Seventy-five micrograms of cellular protein extracted from SCLC cell line NCI-H209 (lane 1) and from a control non-SCLC cell line NCI-H522 (lane 2) were immunoblotted to nitrocellulose after separation on 7.5% SDS/PAGE and incubated with an anti-*RB1* monoclonal antibody, as described. (B) Immunoprecipitation analysis. Anti-*RB1* immunoprecipitates of NCI-H209 cells (lanes 1 and 3) or a control lung carcinoma cell line (lanes 2 and 4) were radiolabeled with [35 S]methionine (lanes 1 and 2) or [32 P]orthophosphate (lanes 3 and 4).

grated on one-dimensional SDS/PAGE with the unphosphorylated form of wild-type RB1 (2) (Fig. 1*B*; lanes 1 and 2). In addition, immunoprecipitations performed on parallel H209 cultures incubated with [32 P]orthophosphate showed a marked decrease in detectable phosphorylated RB1 (Fig. 1*B*; lanes 3 and 4).

To determine whether the anomalous gel migration of RB1 in H209 cells was due to a structural alteration of its coding sequence, we performed RNase protection analysis. Using an *in vitro* transcription vector derived from the plasmid p0.9r (32), containing an insert from the 5' end of the *RB1*-encoded open reading frame (exons 1–9), we observed full-length protection of the antisense RNA probe (consistent with wild-type sequence) in mRNA extracted from H209 (data not shown). In contrast, we found evidence for a potential mutation in H209 cells with the plasmid pJD18. This vector, containing an *RB1* insert spanning from exon 9 to exon 23 (nucleotide coordinate 1039–2537), was linearized at an internal *Nco*I site (coordinate 1681), and a [32 P]UTP uniformly labeled antisense RNA probe was generated (Fig. 2). Full-length protection (consistent with a wild-type sequence) was observed using RNA extracted from a non-small cell-lung cancer line (lane 1) and absence of probe protection (consistent with the absence of detectable RB1 transcripts) was observed with RNA obtained from an unrelated SCLC line (lane 2). In contrast, RNase analysis of cytoplasmic RNA from H209 showed two smaller, protected bands (lane 4) mapping the approximate location of a potential nucleotide mismatch. RNA extracted from a lymphoblastoid cell line




FIG. 2. RNase protection assay. Twenty micrograms of total cellular RNA was extracted from the non-SCLC cell line H522 (lane 1), SCLC lines H187 (lane 2), H209 (lane 4), and a lymphoblastoid cell line (designated in our laboratory as BL-2) derived from the normal peripheral blood of the patient who developed the SCLC tumor H209 (lane 3). The plasmid was linearized at the internal *Nco*I site, and the antisense RNA probe generated spanned *RB1* nucleotide coordinates 2537–1681. Size markers represent pBR322 digested with the restriction enzyme *Hinf*I. Arrows, smaller protected bands mapping the approximate location of a potential nucleotide mismatch.

derived from the normal peripheral lymphocytes of the patient from whom the H209 SCLC tumor originated demonstrated full-length protection consistent with wild-type sequence in the germ-line-transcribed *RB1* (lane 3). The two closely spaced bands sized at ≈ 400 base pairs (bp) seen in all lanes are “background bands” intrinsic to full-length protection of the probe, as they are also seen when the probe was hybridized to wild-type cloned *RB1* and subjected to a similar analysis (data not shown).

To identify the specific mutation predicted by the RNase protection analysis, we conducted PCR amplification of first-strand cDNA synthesized from cytoplasmic RNA from H209 cells. Nucleotide sequence analysis revealed a single G \rightarrow T point mutation at position 2255, corresponding to the location predicted by the RNase protection studies (Fig. 3*A*). The same mutation was seen in seven different *RB1*-containing subclones of H209 cells generated from three independent PCR reactions by using RNA extracted at different cell passages. This confirms that the mutation observed was not a result of an incorporation artifact and also suggests that only the mutated allele is expressed in this cell line. The full-length protection band seen on the RNase protection study (lane 4), therefore, is probably due to incomplete digestion of a single nucleotide mismatch by RNase A. To exclude the possibility of additional somatic mutations, we examined the entire open reading frame of the transcribed *RB1* in cell line H209 by nucleotide sequencing of PCR-amplified cDNA and RNase protection analysis and did not find any other mutations. We then examined the effect this point mutation would have on the predicted encoded amino acid sequence and found a nonconservative amino acid substitution of cysteine by phenylalanine at codon 706 near the beginning of exon 21 (Fig. 3*B*).

To investigate whether this amino acid change is directly responsible for the phosphorylation defect and not the result




FIG. 3. (A) Partial nucleotide sequence of *RB1* transcribed in cell line H209 demonstrating the G \rightarrow T point mutation. No other mutation was observed through the rest of the encoded open reading frame. (B) Partial amino acid sequence of exon 21 in cell line H209 demonstrating the Cys \rightarrow Phe substitution.

of an RB1 kinase system abnormality in H209 cells, we constructed eukaryotic expression vectors that contained either the open reading frame of the wild-type *RB1* sequence or the mutant sequence as determined in cell line H209. An unrelated SCLC cell line, H187, which had previously been shown to be *RB1*⁻ secondary to a homozygous structural alteration (7) was transfected with either the wild-type or mutant expression vector. After selection in G418 and expansion of single cell clones, cellular extracts were assayed on immunoblots for the presence of exogenous RB1 (Fig. 4). As predicted, the wild-type *RB1*-containing expression vector generated exogenous RB1 with the expected migration on SDS/PAGE of a normal phosphorylation pattern seen with endogenous RB1. In contrast, the mutant vector resulted in the expression of only the underphosphorylated 110-kDa form as seen *in vivo* with the H209 cells. We have concluded from these results that substitution of Cys-706 → Phe is sufficient to disrupt the phosphorylation of RB1.

Given that the amino acid substitution in H209 was localized to a region of the RB1 thought important for protein-protein interactions (exon 21), we sought to determine whether the H209 RB1 was impaired in its ability to associate with simian virus 40 large tumor antigen or adenovirus E1A. As we have previously shown, association of wild-type RB1 with either oncoprotein will result in coprecipitation of RB1 using antibodies directed against the viral oncoproteins (2, 10, 15). To perform these experiments, wild-type and the H209 mutant RB1 cloned DNA were subjected to *in vitro* transcription and translation in the presence of [³⁵S]methionine. Radiolabeled translation products were then incubated with buffer alone or nonradioactive cell lysates containing either E1A (human 293 cells) or simian virus 40 large tumor antigen (monkey COS cells). After incubation, lysates were challenged with antibodies directed against RB or one of the two viral oncoproteins. As shown in Fig. 5, anti-RB1 antiserum produced identical patterns of immunoprecipitated RB1 from both wild-type and mutant RB1 translation reactions. However, whereas the wild-type protein was capable of noncovalently binding to the transforming proteins of these DNA tumor viruses, the single amino acid change seen in line H209 completely abolishes this protein-protein interaction.

DISCUSSION

Inactivation of *RB1* appears to play a critical role in the genesis of pediatric retinoblastoma tumors and may also




FIG. 4. G418-resistant clones transfected with wild-type and H209 mutant *RB1*-containing expression vectors. Cellular protein (75 μ g) was extracted from transfected clones and immunoblotted with an anti-RB1 monoclonal antiserum after electrophoretic separation by SDS/PAGE. Lanes: 1, H187 cells after transfection with wild-type *RB1*-containing expression vector; 2, H187 cells; 3, normal control (non-SCLC line NCI-H522); 4, H187 cells after transfection with H209 mutant RB1 expression vector; 5, H209 cells.




FIG. 5. Immunoprecipitation of RB1 incubated in the presence of large-tumor (T) and adenovirus E1A transforming proteins. Plasmids with the wild-type (Wt) or mutant (209) *RB1* open reading frame were *in vitro* transcribed and translated as described. The labeled RB1 was then incubated with nonradioactive cell lysates containing either SV40 large tumor (+T) or adenovirus E1A (+E1A) proteins followed by immunoprecipitation with anti-RB1 (α Rb), anti-large T (α T), or anti-E1A (α E1A) antisera and electrophoretic separation by SDS/PAGE.

participate in the development of other common, adult malignancies. Although the model of the RB1 as a regulator of cell growth is widely accepted, our understanding of the functional role of this protein product is still limited. Previous experiments have shown that the protein is localized to the nucleus, has a half-life of >6 hr, and appears to bind deoxynucleic acids in a nonspecific manner (1, 10). Other features of RB1 are that it can bind to the oncoproteins of at least three DNA tumor viruses (15–19) and that the catalysis of RB1 phosphorylation and dephosphorylation modifications is tightly associated with specific stages of the cell cycle (20–24).

One approach to help elucidate more detailed information about the structure-function of this anti-oncogene is to characterize *in vivo* mutant protein products. NCI-H209 tumor cells, producing an aberrant RB1 due to a missense mutation, represents a cell line with a unique type of defective RB1. Previous analyses of truncated RB1s have revealed several mutants lacking specific segments of the encoded open reading frame due to exon-splicing mutations. Although it has been suggested that such aberrant molecules are functionally inactivated through loss of critical residues within the 73 amino acids encoded by exons 21 and 22, it was still conceivable that this region had a propensity, via unknown mechanisms, for mutations inducing splicing errors. The missense mutation identified near the beginning of exon 21 in H209 cells suggests, instead, a functional role for this region of RB1, particularly in the vicinity of codon 706. This residue also lies within an RB1 domain (amino acids 646–772) identified recently by *in vitro* deletion mutants to be required for oncoprotein binding (33). The Cys-706 → Phe substitution appears to simultaneously abrogate RB1 phosphorylation and affinity for viral oncoproteins. As such, we might also conclude that the *RB1* product expressed in these tumor cells is also defective in performing "normal" cellular functions as well. Lack of RB1 phosphorylation alone cannot cause the loss of simian virus 40 large tumor and adenovirus E1A binding because both viral oncoproteins complex with dephosphorylated RB1 (15, 16, 25). That this single amino acid

substitution within exon 21 has such profound effects is consistent with a model where Cys-706 plays a key role, perhaps through a disulfide bond, in determining a three-dimensional conformation essential for protein-protein interactions. Alternatively, Cys-706 may not participate in disulfide bonding and instead, with neighboring residues, may be an important contact point for the RB1 kinase system and RB1-oncoprotein interactions. Given its phosphorylation deficiency, protein produced from NCI-H209 cDNA should prove to be a valuable reagent in the characterization of putative kinases and phosphatases that may interact with and presumably regulate RB1 activity.

We thank J. Dunn and B. Gallie for their gift of the pJD18 plasmid, W.-H. Lee for advice on preparation of cellular protein extracts, J. Fedorko for oligonucleotide synthesis and assistance with immunoblotting, and J. Minna for support and encouragement.

1. Lee, W.-H., Shew, J.-Y., Hong, F. D., Sery, T. W., Donoso, L. A., Young, L.-J., Bookstein, R. & Lee, E. Y.-H. P. (1987) *Nature (London)* **329**, 642-645.
2. Horowitz, J. M., Park, S.-H., Bogenmann, E., Cheng, J.-C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P. & Weinberg, R. A. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 2775-2779.
3. Bernards, R., Shackleford, G. M., Gerber, M. R., Horowitz, J. M., Friend, S. H., Schartl, M., Bogenmann, E., Rapaport, J. M., McGee, T., Dryja, T. P. & Weinberg, R. A. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 6474-6478.
4. Horowitz, J. M., Park, S.-H., Yandell, D. W. & Weinberg, R. A. (1989) in *Recessive Oncogenes and Tumor Suppression*, eds. Hastie, N., Cavence, W. & Stanbridge, E. (Cold Spring Harbor Lab., Cold Spring Harbor, NY), pp. 101-107.
5. Knudson, A. F., Jr. (1971) *Proc. Natl. Acad. Sci. USA* **68**, 820-823.
6. Cavenee, W. K., Dryja, T. P., Phillips, R. A., Benedict, W. F., Godbout, R., Gallie, B. L., Murphree, A. L., Strong, L. C. & White, R. L. (1983) *Nature (London)* **305**, 779-784.
7. Harbour, J. W., Lai, S., Whang-Peng, J., Gazdar, A. F., Minna, J. D. & Kaye, F. J. (1988) *Science* **241**, 353-357.
8. Yokota, J., Akiyama, T., Fung, Y.-K. T., Benedict, W. F., Namba, Y., Hanaoka, M., Wada, M., Terasaki, T., Shimosato, Y., Sugimura, T. & Terada, M. (1988) *Oncogene* **3**, 471-475.
9. Friend, S. H., Horowitz, J. M., Gerber, M. R., Wang, X.-F., Bogenmann, E., Li, F. P. & Weinberg, R. A. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 9059-9063.
10. Horowitz, J., Yandell, D. W., Park, S.-H., Canning, S., Whyte, P., Buchkovich, K., Harlow, E. & Weinberg, R. A. (1989) *Science* **243**, 937-940.
11. Lee, E. Y.-H. P., To, H., Shew, J.-Y., Bookstein, R., Scully, P. & Lee, W.-H. (1988) *Science* **241**, 218-221.
12. T'Ang, A., Varley, J. M., Chakraborty, S., Murphree, A. L. & Fung, Y.-K. T. (1988) *Science* **242**, 263-266.
13. Bookstein, R., Shew, J.-Y., Chen, P.-L., Scully, P. & Lee, W.-H. (1990) *Science* **247**, 712-715.
14. Huang, H.-J. S., Yee, J.-K., Shew, J.-Y., Chen, P.-L., Bookstein, R., Friedman, T., Lee, E. Y.-H. P. & Lee, W.-H. (1988) *Science* **242**, 1563-1566.
15. Whyte, P., Buchovich, J. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A. & Harlow, E. (1988) *Nature (London)* **334**, 124-129.
16. DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J., Huang, C., Lee, W., Marsilio, E., Paucha, E. & Livingston, D. M. (1988) *Cell* **54**, 275-283.
17. Dyson, N., Howley, P. M., Munger, K. & Harlow, E. (1989) *Science* **243**, 934-937.
18. Egan, S., Bayley, S. T. & Branton, P. E. (1989) *Oncogene* **4**, 383-388.
19. Gage, J. R., Meyers, C. & Wettstein, F. O. (1990) *J. Virol.* **64**, 723-730.
20. Buchkovich, K., Duffy, L. A. & Harlow, E. (1989) *Cell* **58**, 1097-1105.
21. Chen, P.-L., Scully, P., Shew, J.-W., Wang, J. Y. J. & Lee, W.-H. (1989) *Cell* **58**, 1193-1198.
22. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwinica-Worms, H., Huang, C.-M. & Livingston, D. M. (1989) *Cell* **58**, 1085-1095.
23. Mihara, K., Cao, X.-R., Yen, A., Chandler, S., Driscoll, B., Murphree, A. L., T'Ang, A. & Fung, Y.-K. T. (1989) *Science* **246**, 1300-1303.
24. Ludlow, J. W., Shon, J., Pipas, J. M., Livingston, D. M. & DeCaprio, J. A. (1990) *Cell* **60**, 387-396.
25. Ludlow, J. W., DeCaprio, J. A., Huang, C., Lee, W., Paucha, E. & Livingston, D. M. (1989) *Cell* **56**, 57-65.
26. Shew, J.-Y., Chen, P.-L., Bookstein, R., Lee, E. Y.-H. P. & Lee, W.-H. (1990) *Cell Growth Diff.* **1**, 17-25.
27. Carney, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., Zieg, M. H. & Minna, J. D. (1985) *Cancer Res.* **45**, 2913-2923.
28. Sanger, F., Nicklen, S. & Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 5463-5467.
29. Harlow, E., Franza, B. R., Jr., & Schley, C. (1985) *J. Virol.* **55**, 533-546.
30. Harlow, E., Crawford, L. V., Pim, D. C. & Williamson, N. M. (1981) *J. Virol.* **39**, 861-869.
31. Kaye, F. J., Battey, J., Nau, M., Brooks, B., Seifter, E., DeGreve, J., Birrer, M., Sausville, E. & Minna, J. (1988) *Mol. Cell. Biol.* **8**, 186-195.
32. Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Alberts, D. M. & Dryja, T. P. (1986) *Nature (London)* **323**, 643-646.
33. Hu, Q., Dyson, N. & Harlow, E. (1990) *EMBO J.* **9**, 1147-1155.



- DatabasesTools
- Help
- General Help
- Formats
- Gaps
- Matrix
- References
- EMBOSS-Align Help

All DatabasesEnter Text Here

Reset ?Give us feedback

Advanced Search

EBI GroupsTrainingIndustryAbout UsHelp

Site Index

EMBOSS Align Results

Needle Results	
Matrix	Blosum62
Open gap penalty	10.0
Gap extension penalty	0.5
Needle output	needle-20081031-14070669390134.output
SUBMIT ANOTHER JOB	

```
#####
# Program: needle
# Rundate:  Fri Oct 31 14:07:07 2008
# Align_format: srspair
# Report_file: /ebi/extserv/old-work/needle-20081031-14070669390134.output
#####

#=====
#
# Aligned_sequences: 2
# 1: EMBOSS_001
# 2: EMBOSS_001
# Matrix: EBLOSUM62
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 4651
# Identity:      333/4651 ( 7.2%)
# Similarity:    464/4651 (10.0%)
# Gaps:          3885/4651 (83.5%)
# Score: 1438.0
#
#
#=====

EMBOSS_001      1                                     0
EMBOSS_001      1 mltpplllllpllsalvaaaidapktcspkqfacrdqitciskgwrcdge      50
EMBOSS_001      1                                     0
EMBOSS_001     51 rdcpdgsdeapeicpqskaqrcqpnehncigtelcvpmsrlcngvqdcmd      100
EMBOSS_001      1                                     0
EMBOSS_001    101 gsdegphcrelqgncsrlgcqhhcvtldgptcycnssfqlqadgktckd      150
EMBOSS_001      1                                     0
EMBOSS_001    151 fdecsvygtcsqlctntdgsficgcvegylldpnrscaknepvdrppv      200
EMBOSS_001      1                                     0
EMBOSS_001    201 lliansqnilatylsgaqvstitptstrqtamdfsyanetvcwvhvgds      250
EMBOSS_001      1                                     0
EMBOSS_001    251 aaqtqlkcarmpglkgfvdehtinislslhvEqmaidwltgnfyfvddi      300
EMBOSS_001      1                                     0
EMBOSS_001    301 ddriFvcnrngdctvtllldelYnpkgialdpamgkvfftDyqqipkver      350
```

EMBOSS_001	1	0
EMBOSS_001	401 rgtiiqgiliehlygltfenylyatnsdnanaqqktsvirvnrfnstey	450
EMBOSS_001	1	0
EMBOSS_001	451 qvvtrvdkggalhiyhqrrqprvrshacendqygkpggcsdicllanshk	500
EMBOSS_001	1	0
EMBOSS_001	501 artcrrcrgfslgsdgksckkpehelflvygkgrpgiirgmdmgakvpde	550
EMBOSS_001	1	0
EMBOSS_001	551 hmipienlmnpraldfhaetgfifyfadttstyligrqkidgteretilkdg	600
EMBOSS_001	1	0
EMBOSS_001	601 ihnvegvavdwmgdonlywtddgpkktisvarlekaaqrkrtliegkmthp	650
EMBOSS_001	1	0
EMBOSS_001	651 raivvdplngwmywtdweedpkdsrrgrlerawmdgshrdifvtsktvlw	700
EMBOSS_001	1	0
EMBOSS_001	701 pnglsldipagrlywvdafydrietillngtdrkivyegpelnhafglch	750
EMBOSS_001	1	0
EMBOSS_001	751 hgnylfwteyrsgsvyrlergvvgapptvtllrserppifeirmyaqqq	800
EMBOSS_001	1	0
EMBOSS_001	801 qvgtnkcrvnnggcsslclatpgsrqcacaeqvl dadgvtclanpsyvp	850
EMBOSS_001	1	0
EMBOSS_001	851 ppqcqpgefacanrciqerwkcdgdndcl dnsdeapalchqhtcpsdrf	900
EMBOSS_001	1	0
EMBOSS_001	901 kcennrcipnrwlcgdndcgn sedesnatcsartcppnqfscasgrcip	950
EMBOSS_001	1	0
EMBOSS_001	951 iswtcdldddcgdrsdasacayptcfpl tqftcnngrcininwrcdndn	1000
EMBOSS_001	1	0
EMBOSS_001	1001 dcdgnsdeagcshscsstqfkcnsgrcipehwtcdgdndcg dysdethan	1050
EMBOSS_001	1	0
EMBOSS_001	1051 ctngatrppggchtdefqcrldglciplr wrcdgdtdcmdssdekscegv	1100
EMBOSS_001	1	0
EMBOSS_001	1101 thvcdpsvkfgckdsarciskawvcdgdndcednsdeenceslac rppsh	1150
EMBOSS_001	1	0
EMBOSS_001	1151 pcanntsvclppdklcdgnddcgdgsdegelcdqcslnnggcshncsvap	1200
EMBOSS_001	1	0
EMBOSS_001	1201 gegivcscplgmelgpdnhtcqiqsycakhlkcsqkcdqnkfsvkcsye	1250
EMBOSS_001	1	0
EMBOSS_001	1251 gwrlendagagvldnflkfiifsnrheirridl hkdagvulmclnti	1300

EMBOSS_001	1301	aldfhlsqsalwytdvvedkiyrgklldngaltsfevviqyglatpegla	1350
EMBOSS_001	1		0
EMBOSS_001	1351	vdwiagniywvesnldqievakldgtlrrttllagdiehpraialdprdgi	1400
EMBOSS_001	1		0
EMBOSS_001	1401	lfwtdwdaslprieaasmagarrtvhretgsggwpngltvdylekrilw	1450
EMBOSS_001	1		0
EMBOSS_001	1451	idarsdaiysarydgsghmevlrgheflshpfavtlyggevywtdwrtnt	1500
EMBOSS_001	1		0
EMBOSS_001	1501	lakankwtghnvtvvqrntntqpfldqvvyhpsrqpmappnceanggggpcs	1550
EMBOSS_001	1		0
EMBOSS_001	1551	hlclinyntvscacphlmklhkdnnttcyefkkflllyarqmeirgvldda	1600
EMBOSS_001	1		0
EMBOSS_001	1601	pyynyisftvpdidnvtvldydaregrvywsdvrtqaikrafingtve	1650
EMBOSS_001	1		0
EMBOSS_001	1651	tvvsadlpnahglavdwvsrnlfwtsydnkkqinvarldgsfknavvqg	1700
EMBOSS_001	1		0
EMBOSS_001	1701	leqphglvvhplrgklywtgdgnismanmdgsnrtilfsgqkgpvglaid	1750
EMBOSS_001	1		0
EMBOSS_001	1751	fpeklywissgnhtinrcnldgsglevidamrsqldgkatalaimgdklw	1800
EMBOSS_001	1		0
EMBOSS_001	1801	wadqvsekmgtsckadgsgsvvlrnsttlvmhmkydesiqldhkgtnpc	1850
EMBOSS_001	1		0
EMBOSS_001	1851	svnngdcsqldclptsettrscmctagyslrsgqqacegvgflllysvheg	1900
EMBOSS_001	1		0
EMBOSS_001	1901	irgipldpndksdalvpvsgtslavgidfhaendtiywvdmglstisrak	1950
EMBOSS_001	1		0
EMBOSS_001	1951	rdqtwredvvtngigrvegiavdwiagniywtdqgfdvievarlngsfry	2000
EMBOSS_001	1		0
EMBOSS_001	2001	vvisqgldkpraitvhpekgyflfwtewgqypriersrldgtervvlnvs	2050
EMBOSS_001	1		0
EMBOSS_001	2051	iswpngisvdyqdgklywcdartdkieridletgenrevvlssnmmdmfs	2100
EMBOSS_001	1		0
EMBOSS_001	2101	vsvfedfiywsdrthangsikrgskdnatdsvglrtgigvqlkdikvfnr	2150
EMBOSS_001	1		0
EMBOSS_001	2151	drqkgtnvcavanggcqqlclyrgrgqracacahgmlaedgascreyagy	2200
EMBOSS_001	1		0

EMBOSS_001	2251	tpnriffsdihfigniqqinddgsrritivenvgsveglayhrghwdtlywt	2300
EMBOSS_001	1		0
EMBOSS_001	2301	syttstitrhtvdqtrpgaferetvitmsgddhprafvldecqnlmfwn	2350
EMBOSS_001	1		0
EMBOSS_001	2351	wneqhpsimraalsganvltliekdiptnglaidhraeklyfsdatldk	2400
EMBOSS_001	1		0
EMBOSS_001	2401	ierceydgshryvilksepvhpfglavygehifwtdwvrravqranks	2450
EMBOSS_001	1		0
EMBOSS_001	2451	snmkllrvdipqqpmgiavandtncscelspcrinnggcqdlcllthqgh	2500
EMBOSS_001	1	mgtsalwalwlllalcw	17
EMBOSS_001	2501	vncscrgrgilqddltcravnsscraqdefecangecinfsl-----tc-	2544
EMBOSS_001	18	apresgatgtgrka-----kcepsqfqtngrcit-llwkcdgde	56
EMBOSS_001	2545	----dgvpchckdksdekpsycnsrckktfrqcsngrcvsnmlw-cngad	2589
EMBOSS_001	57	dcvdgsdekncvkktaesdfvcnnggcvsprwkcdgdpdcdedsde---	103
EMBOSS_001	2590	dcdgdsdeipcnktacgvgefrcrdgtcignssrcnqfvdcedasdemnc	2639
EMBOSS_001	104	speqchm-----rtcriheis-----cgahstq----	126
EMBOSS_001	2640	satdcssyfrlgvgkvlfpccertslyapswwcdgandcgdsyderdcp	2689
EMBOSS_001	127	-----cipvswrcdgendcdsgedeencgnitcspde	158
EMBOSS_001	2690	gvkrprcplnyfacpsgrcipmswtcdkeddcehgedethc-nkfcsea	2738
EMBOSS_001	159	ftcssgrcissrnfvengqddcdsgdsde-ldcapptcgahefqc-stssci	206
EMBOSS_001	2739	fecqnhrcciskqwlcdgsddcdgdsdeaahcegkctcgpssfsfcpgthcv	2788
EMBOSS_001	207	piswvcdddadcdsgdsdesleq-cgrqpvihkcpaseiqcgsgecihkk	255
EMBOSS_001	2789	perwlcgdgdkdcadgadesiaagc----lynstcddrefmcqnrqcipkh	2834
EMBOSS_001	256	wrcdgdpdckdgsde-vncpsrtcrpdqfecedgscihgsrq--cngird	302
EMBOSS_001	2835	fvcdhdrdcadgsdespeceyptcgpsefrangrcl-ssrqwecdgend	2883
EMBOSS_001	303	cvdgsdev---nckn-vnqclgpgkfkcrsgecidiskvcnqegeqdcrdw	347
EMBOSS_001	2884	chdqsdeapknphctspehkcncassqflcssgrcvaeallcngqddcdgs	2933
EMBOSS_001	348	sdeplkechineclvnn-ggcshickdlvigyecdcaagfel-idrktcg	395
EMBOSS_001	2934	sde--rgchineclsrklsgcsqdcclkgfkcrcrpgfrlkdgrtca	2981
EMBOSS_001	396	didecqnpgicsqicinkggykcecsrgyqmdlatg---vckav-gke	440
EMBOSS_001	2982	dvdecsttfpcsqrcinthsykcclcvegy---aprggdphsckavtdee	3028
EMBOSS_001	441	psliftnrddirkeyigrlveqlrntvaldadiaaqklfwadlsq	490
EMBOSS_001	3029	pflifanryylrklnldgsnytlkqglnavaldfdyreqmiywtvtt	3078
EMBOSS_001	491	kaifsasiddkv---grhvkmi--dnvynpaaiavdwvyktywtdaask	535
EMBOSS_001	3079	q---gsmirrmhlngsnvqvlhrtglsnpgdlavdwvggnylwcckgrd	3124
EMBOSS_001	536	tigvatldgtrkylfnedlrenasjauddlccfnnwcdwgenakiakag	595

EMBOSS_001	586	mngfdrplvtadiqwpngitldlikrslywldskhlmlssvdlngqdr	635
EMBOSS_001	3175	mdgssrsvivdtkitwpgltldyvteriywadaredyiefasldgsnrh	3224
EMBOSS_001	636	ivlksleflahplaltifedrvywidgeneavygankftgselatlvnnl	685
EMBOSS_001	3225	vvls--qdiphifaltlfdyvywtldwetksinrahkttgtnktllistl	3272
EMBOSS_001	686	ndaqdiiivyhelvqpsgknw-ceedmenggceylclpapqindhspkytc	734
EMBOSS_001	3273	hrpmdlhvfhalrqpdvphnck--vnnggcsnlcclsp-----ggghkc	3315
EMBOSS_001	735	scpsgynveengrdcqstattvtysctkdtntteisatsglvpgginvtt	784
EMBOSS_001	3316	acptnfylgsdgrtcvsncta-----	3336
EMBOSS_001	785	avsevsppkgtsaawailpllllvmaavggylmwrnwqhknkmksmfn	834
EMBOSS_001	3337	-----sqfvckndkci----	3347
EMBOSS_001	835	pvykttedlsidigrhs-----asvg-htypaisvv	866
EMBOSS_001	3348	pfwwkcdted---dcgdsdeppdcpefkcrpgqfqcstgictnpaf-ic	3393
EMBOSS_001	867	stddla	873
EMBOSS_001	3394	dgndcdqnsdeancdihvclpsqfkcctntnrcipgifrcngqdcgde	3443
EMBOSS_001	874		873
EMBOSS_001	3444	derdcpevtcapnqfcsitkrciprvwvcdndcvdgsdepanctqmt	3493
EMBOSS_001	874		873
EMBOSS_001	3494	cgvdefrckdsgrciparwkcdgeddcgdsdepkeecdertcepyqfrc	3543
EMBOSS_001	874		873
EMBOSS_001	3544	knnrcvpgrwqcdyndcgdsndeesctprpcsesefscangrciagrwk	3593
EMBOSS_001	874		873
EMBOSS_001	3594	cdgdhdcadgsdekdtprcdmdqfqccksghciprlwrccdadacmdgsd	3643
EMBOSS_001	874		873
EMBOSS_001	3644	eeacgtgvrtcpldefqcnntlckplawkcdgeddcgdsndenpeecarf	3693
EMBOSS_001	874		873
EMBOSS_001	3694	vcppnrpfrckndrvclwigrqcdgtndcgdtdeedcepptahthckd	3743
EMBOSS_001	874		873
EMBOSS_001	3744	kkeflcrnqrclssslrcnmfddcgdsdeedcsidpkltscatnasicg	3793
EMBOSS_001	874		873
EMBOSS_001	3794	dearcvrtekaaycacrsghftvpggpgcdineclrfgtcsqclcnntkg	3843
EMBOSS_001	874		873
EMBOSS_001	3844	ghlscarnfmkthntckaegseyqvlyiaddneirslfpghphsayeqa	3893
EMBOSS_001	874		873
EMBOSS_001	3894	fqgdesvridamdvhvkagrvywtwnhtgtisyrslppaappttsnrhrr	3943
EMBOSS_001	874		873
EMBOSS_001	3944	qidrgvthlnisglkmprgiaidwvagnvywtldsgrdvievaqmkgenrk	3993

EMBOSS_001	874	873
EMBOSS_001	4044 iqwptglavdyhnerlywadaklsvigsirlngtdpivaadskrglshpf	4093
EMBOSS_001	874	873
EMBOSS_001	4094 sidvfedyiygvtyinnrvfkihkfghsplvnlgtgglshasdvlyhghk	4143
EMBOSS_001	874	873
EMBOSS_001	4144 qpevtnpcdrkkcewlcllspsgpvctcpngkrlndngtcvpvpsptpppd	4193
EMBOSS_001	874	873
EMBOSS_001	4194 aprpgtcnlqcfnggscflnarrqpkcrcqprytgdkceldqcwehcrng	4243
EMBOSS_001	874	873
EMBOSS_001	4244 gtcaaspsgmptcrcptgftgpkctqqvcagycannstctvnqgnqpqcr	4293
EMBOSS_001	874	873
EMBOSS_001	4294 clpgflgdrcqyrqcsygenfgtcqmaadgsrqrcrtayfegsrcevnk	4343
EMBOSS_001	874	873
EMBOSS_001	4344 csrclcgacvvnkqsgdvtcnctdgrvapscltcvghcsnggsctmnsk	4393
EMBOSS_001	874	873
EMBOSS_001	4394 mpecqcpphmtgprceehvfsqqqpgghiasiliplllllllavlvgvfw	4443
EMBOSS_001	874	873
EMBOSS_001	4444 ykrrvqgakgfqhqrmtngamnveignptykmyeggepddvglldadfa	4493
EMBOSS_001	874	873
EMBOSS_001	4494 ldpdkptnftnpvyatlymgghgsrhlslastdekrellgrgpedeigdpl	4543
EMBOSS_001	874 873	
EMBOSS_001	4544 a 4544	

#-----
#-----